Horizon Discovery (with headquarters in Cambridge, UK and Dharmacon manufacturing in Lafayette, CO) drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine.
Horizon brings expertise in gene editing, gene modulation and cell engineering, providing cell line derived reference standards to the life science community for basic research, internal QC, and assay development and validation. Over 1000 gene variants reside in our collection, along with ready to use configurations for assay, sample and whole process controls.
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO (gene, peptide, protein, antibody services), enzyme and synthetic biology products, biologics development and manufacturing (Cell line development, leads discovery, leads generation and development), as well as cell therapy.
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for programs ranging from research to clinical trials to commercial applications. Aldevron’s Cas9 nuclease is available as an off-the-shelf product at research grade, GMP Source and GMP quality levels, eliminating months typically associated with contract production. Additional gene editing enzymes will be available in the near future. Aldevron also custom manufactures enzymes, including Cas9 and other nucleases, to meet the most stringent specifications. Company headquarters are in Fargo, ND, with additional facilities in Madison, WI, and Freiburg, Germany. For more information, or to get in touch with our client support team.
Cellecta provides highthroughput loss-of function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA, CRISPR, and barcode libraries;pooled library screening and analysis by NGS; targeted RNA-Seq for biomarker discovery; lentiviral reagents; and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.